Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated

Standard of Care and Acute Management for AIDP

At a Glance

The primary treatments for AIDP are Intravenous Immunoglobulin (IVIG) and plasma exchange, which are equally effective at stopping the immune attack on nerves. About 20-30% of patients require intensive care monitoring for breathing and heart function while they begin to recover.

Treatment for Acute Inflammatory Demyelinating Polyradiculoneuropathy (AIDP) focuses on two main goals: stopping the immune system’s attack on your nerves and supporting your body’s vital functions while the nerves begin to heal. Because AIDP can progress rapidly, treatment is usually started as soon as the diagnosis is suspected [1][2].

First-Line Immunotherapy

There are two primary treatments proven to be effective for AIDP. They are considered equally effective, and the choice between them often depends on what is most available at your hospital and your overall health [3][4].

  • Intravenous Immunoglobulin (IVIG): This is the most common treatment. It involves an infusion of antibodies collected from healthy donors [5]. These “good” antibodies help neutralize the “bad” antibodies that are attacking your nerve insulation [6]. It is usually given over 3 to 5 days. What it feels like: IVIG is given through a standard IV. While often well-tolerated, a common side effect is a severe headache, which your care team can help manage with medication [5][7].
  • Plasma Exchange (TPE or Plasmapheresis): This process uses a machine to filter your blood. It removes the liquid part of your blood (plasma)—which contains the attacking antibodies—and replaces it with a plasma substitute or donor plasma [5][8]. What it feels like: This requires a larger, specialized IV line. During the treatment, some patients feel cold, tired, or experience slight cramping due to shifts in fluid and calcium [3].

Important Note: Combining these two treatments (doing both at once) has not been shown to be more effective than doing just one, and in some cases, it may lead to worse outcomes [9][10].

Why Steroids are Avoided

You may be familiar with corticosteroids (like prednisone) being used for other “inflammatory” conditions. However, in classic AIDP/GBS, clinical trials have repeatedly shown that steroids do not help speed up recovery and are not recommended [11][2]. In fact, some studies suggest they might actually hinder long-term recovery in certain patients.

Acute Management and the ICU

About 20-30% of people with AIDP will need intensive care monitoring [12]. This is a proactive way to keep you safe if the weakness affects your breathing or heart rate.

1. Respiratory Support and the “20/30/40 Rule”

The medical team will perform frequent bedside breathing tests. A respiratory therapist will ask you to blow hard into a plastic tube to measure your lung strength (Vital Capacity and Inspiratory/Expiratory Force) [13].

  • Doctors use these tests to apply the 20/30/40 Rule—specific thresholds that act as a safety net. If your lung strength falls below these numbers, the team will know it is time to provide a ventilator to help you breathe, ensuring you don’t exhaust yourself [14].

2. Monitoring for Heart and Blood Pressure

Because the nerves controlling your heart and blood pressure can be affected, you will be on a continuous heart monitor. The team is looking for sudden changes in heart rate (arrhythmias) or blood pressure swings that may require immediate medication [15][16].

3. Preventing Physical Complications

When you are suddenly paralyzed or confined to a bed, your body faces immediate physical risks [17]. Your care team should implement a strict protocol for:

  • Blood Clot (DVT) Prevention: You will likely receive blood-thinning injections (like heparin) and wear inflatable compression boots on your legs to keep blood circulating.
  • Bedsore Prevention: Nurses will turn and reposition you every few hours to prevent painful pressure ulcers on your skin.

What If the First Treatment Doesn’t Work?

If a patient does not show improvement after the first round of IVIG, it is natural to want more. However, recent large-scale clinical trials (like the SID-GBS trial) have shown that a second course of IVIG does not provide extra benefit and may increase the risk of side effects [18][19]. Instead, the focus remains on high-quality supportive care, rehabilitation, and patience while the body naturally begins the healing process [19].

(Return to the Home Page)

Common questions in this guide

Which is better for AIDP: IVIG or plasma exchange?
Intravenous Immunoglobulin (IVIG) and plasma exchange are considered equally effective for treating AIDP. The choice usually depends on your overall health and which treatment is readily available at your hospital.
Why aren't steroids used to treat AIDP?
Clinical trials have shown that corticosteroids, like prednisone, do not speed up recovery in classic AIDP. In fact, some studies suggest they may actually hinder long-term recovery for certain patients and are generally avoided.
What is the 20/30/40 rule for breathing in AIDP?
The 20/30/40 rule refers to specific measurements of lung strength taken by a respiratory therapist at your bedside. If your breathing tests fall below these safety thresholds, your care team will know it is time to provide a ventilator to help you breathe so you do not exhaust yourself.
Does getting a second round of IVIG help if the first one didn't work?
Large clinical trials have shown that a second course of IVIG does not provide extra benefit and may increase the risk of side effects. If you do not improve initially, the medical focus shifts to high-quality supportive care and rehabilitation.
How do hospitals prevent blood clots and bedsores if I am paralyzed from AIDP?
Care teams use strict medical protocols to protect immobilized patients. This typically includes blood-thinning injections, inflatable compression boots to keep blood circulating, and nurses physically turning your body every few hours to prevent painful pressure ulcers.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Is my breathing being monitored using bedside tests where I blow into a tube to measure my vital capacity?
  2. 2.Why are we choosing IVIG over plasma exchange (or vice versa) for my specific case?
  3. 3.What criteria will you use to decide if I need to be moved to the Intensive Care Unit (ICU)?
  4. 4.If my condition hasn't improved after the first round of treatment, what is the current evidence regarding a second course of IVIG?
  5. 5.What is the care team's specific plan to prevent blood clots (DVTs) and bedsores while I am immobilized?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee.

    Tavee J, Brannagan TH, Lenihan MW, et al.

    Muscle & nerve 2023; (68(4)):356-374 doi:10.1002/mus.27922.

    PMID: 37432872
  2. 2

    Plasma exchange for Guillain-Barré syndrome.

    Chevret S, Hughes RA, Annane D

    The Cochrane database of systematic reviews 2017; (2()):CD001798 doi:10.1002/14651858.CD001798.pub3.

    PMID: 28241090
  3. 3

    Treatment Efficacy of Plasmapheresis Versus Intravenous Immunoglobulin in Guillain-Barré Syndrome Management: A Systematic Review.

    Savithri Nandeesha S, Kasagga A, Hawrami C, et al.

    Cureus 2024; (16(3)):e57066 doi:10.7759/cureus.57066.

    PMID: 38681292
  4. 4

    Nationwide study of therapeutic plasma exchange vs intravenous immunoglobulin in Guillain-Barré syndrome.

    Beydoun HA, Beydoun MA, Hossain S, et al.

    Muscle & nerve 2020; (61(5)):608-615 doi:10.1002/mus.26831.

    PMID: 32052454
  5. 5

    Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin.

    Maheshwari A, Sharma RR, Prinja S, et al.

    Journal of clinical apheresis 2018; (33(6)):631-637 doi:10.1002/jca.21646.

    PMID: 30329175
  6. 6

    Guillain-Barre Syndrome.

    Malek E, Salameh J

    Seminars in neurology 2019; (39(5)):589-595 doi:10.1055/s-0039-1693005.

    PMID: 31639842
  7. 7

    Assessing the comparative efficacy of plasmapheresis and Intravenous immunoglobulin in myasthenia gravis treatment: A systematic review and meta-analysis.

    Ghimire A, Kunwar B, Aryal B, et al.

    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2024; (121()):1-10 doi:10.1016/j.jocn.2024.01.025.

    PMID: 38306763
  8. 8

    Therapeutic plasma exchange as a therapeutic modality for the treatment of IVIG complications.

    Welsh KJ, Bai Y

    Journal of clinical apheresis 2015; (30(6)):371-4 doi:10.1002/jca.21386.

    PMID: 26123478
  9. 9

    Plasma exchange alone versus combination with intravenous immunoglobulin/methylprednisolone pulse therapy in severe systemic rheumatic diseases: a retrospective study.

    Guo J, Li S, Xu H, et al.

    Frontiers in immunology 2024; (15()):1454691 doi:10.3389/fimmu.2024.1454691.

    PMID: 39822247
  10. 10

    Comparative study of various therapeutic modalities for Guillain Barré syndrome in Assiut University Children Hospital.

    Mohy-Eldeen ZM, Ahmad AR, Mahran HH, Saad K

    The Turkish journal of pediatrics 2020; (62(6)):962-969.

    PMID: 33372434
  11. 11

    [Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report].

    Hashimoto R, Ueda T, Tsuji Y, et al.

    Rinsho shinkeigaku = Clinical neurology 2020; (60(11)):773-777 doi:10.5692/clinicalneurol.cn-001444.

    PMID: 33115993
  12. 12

    International Validation of the Erasmus Guillain-Barré Syndrome Respiratory Insufficiency Score.

    Doets AY, Walgaard C, Lingsma HF, et al.

    Annals of neurology 2022; (91(4)):521-531 doi:10.1002/ana.26312.

    PMID: 35106830
  13. 13

    Clinico-epidemiological profile and prediction of outcome in children with Guillain-Barre syndrome.

    Priyadarshini D, Anuhya V, Mahapatra A

    Italian journal of pediatrics 2025; (51(1)):179 doi:10.1186/s13052-025-02037-0.

    PMID: 40483522
  14. 14

    Clinical Features Indicating the Need for Mechanical Ventilation in Patients with Guillain Barre Syndrome.

    Umer SR, Nisa Q, Kumari M, et al.

    Cureus 2019; (11(8)):e5520 doi:10.7759/cureus.5520.

    PMID: 31687295
  15. 15

    Guillain-Barre Syndrome in Children and Adolescents.

    Langille MM

    Advances in pediatrics 2023; (70(1)):91-103 doi:10.1016/j.yapd.2023.04.001.

    PMID: 37422300
  16. 16

    Guillain-Barré syndrome complicated by takotsubo cardiomyopathy: an under-recognised association.

    Jones T, Umaskanth N, De Boisanger J, Penn H

    BMJ case reports 2020; (13(2)) doi:10.1136/bcr-2019-233591.

    PMID: 32060115
  17. 17

    Augmented reality assisted physiotherapy rehabilitation in early phase of guillain barre syndrome (AIDP)-a case report.

    Shah R, Samal S

    BMC neurology 2026; (26(1)).

    PMID: 41629798
  18. 18

    Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review.

    Prado MB, Adiao KJB, Turalde CWR, Dasig DA

    Acta neurologica Belgica 2024; (124(4)):1237-1250 doi:10.1007/s13760-024-02518-9.

    PMID: 38553651
  19. 19

    Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.

    Walgaard C, Jacobs BC, Lingsma HF, et al.

    The Lancet. Neurology 2021; (20(4)):275-283 doi:10.1016/S1474-4422(20)30494-4.

    PMID: 33743237

This page provides educational information about standard AIDP treatments and acute medical management. It does not replace professional medical advice or emergency care from your healthcare team.

Get notified when new evidence is published on Acute inflammatory demyelinating polyradiculoneuropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.